September 13-15, 2019, Cord Blood Connect-2019, an international cord blood congress, was held in Miami (USA). This important international event was attended by more than 300 doctors, scientists and representatives of the biobanking industry from 33 countries of the world.
The Congress was organized by the Cord Blood Association with the active support of the World Bone Marrow Donor Association and other reputable profile organizations.
The main reports of the Congress were devoted to the latest approaches to the use of umbilical cord blood in practical medicine in children and adults, as well as relevant aspects of organizing the work of biobanks. Considerable attention was paid to the quality of cord blood stem cell transplants, their proper screening before clinical use, and transportation to clinical centers.
Among the latest approaches to cell and tissue biobanking, Australian scientists have presented the experience of organizing a bank of induced pluripotent stem cell lines , derived from umbilical cord blood. In 2012, Japanese scientist Shinya Yamanaka and British scientist John Gerdon won the Nobel Prize for reprogramming adult cells into induced pluripotent stem cells. The clinical value of induced pluripotent stem cells lies in their unlimited potential, and cord blood has proven to be an ideal source for iPS cells.
In addition to the well-known preparations derived from umbilical cord blood (hematopoietic stem cell transplants, umbilical cord blood T-lymphocytes, platelet gel or artificial tear), a new drug that contains umbilical cord blood macrophages was presented by scientists of the Duke University (USA). This drug is promising for the treatment of genetically determined diseases of metabolism.
Within the framework of the congress, thematic workshops and training of inspectors of the cord blood biobanking industry were held.